

# Table of Contents

## CHAPTER 1. AN INTRODUCTION TO MEDICARE AND MEDICAID FRAUD AND ABUSE

- § 1:1 Introduction
- § 1:2 What is fraud and abuse?
- § 1:3 Who enforces?
- § 1:4 Types of violations and penalties
- § 1:5 What do they tell you in advance?
- § 1:6 Advisory Opinions
- § 1:7 OIG Work Plan
- § 1:8 Model Compliance Guidances
- § 1:9 Fraud Alerts, Bulletins and FAQs
- § 1:10 OIG Further Suggestions
- § 1:11 The new regulatory and enforcement context  
post-Allina
- § 1:12 What triggers enforcement?
- § 1:13 Fraud and abuse in specific industry sectors—  
Physicians
- § 1:14 —Other practitioners
- § 1:15 —Hospitals
- § 1:16 —Nursing facilities
- § 1:17 —Home health, home infusion therapy and hospice
- § 1:18 —Pharmacies, pharmacists, and pharmaceutical  
companies
- § 1:19 —Durable medical equipment, prosthetics, orthotics,  
and supplies
- § 1:20 —Laboratories
- § 1:21 —Managed care/Health plans/Medicare Advantage
- § 1:22 —Other
- § 1:23 Privacy and data
- § 1:24 Medicare Part D
- § 1:25 Enrollment
- § 1:26 Fraud against other health care payers
- § 1:27 Compliance plans
- § 1:28 Compliance guidance from the OIG
- § 1:29 Seven essential ingredients of a successful compliance  
program, generally
- § 1:30 —Clinical laboratories
- § 1:31 —Hospitals
- § 1:32 —Home health agencies

- § 1:33 —Third party billing companies
- § 1:34 —Suppliers of durable medical equipment and supplies
- § 1:35 —Hospices
- § 1:36 —Nursing facilities
- § 1:37 —Medicare+Choice organizations now applicable to Medicare Advantage Plans
- § 1:38 —Individual and small group physician practices
- § 1:39 Compliance program guidance for ambulance suppliers
- § 1:40 Pharmaceutical industry
- § 1:41 General compliance program guidance
- § 1:42 Corporate Integrity Agreements (CIAs)
- § 1:43 Corporate Integrity Agreements and Corporate Compliance Plans compared
- § 1:44 Use of CIAs and Effect on DOJ Enforcement
- § 1:45 Material breach
- § 1:46 Voluntary disclosure
- § 1:47 Practical issues

## **CHAPTER 2. THE ANTI-KICKBACK LAWS**

- § 2:1 Introduction
- § 2:2 The current federal anti-kickback law
- § 2:3 The varied face of unlawful kickback arrangements
- § 2:4 The Social Security Act of 1972
- § 2:5 —Early conflicting judicial views of the anti-kickback statute
- § 2:6 —The *Zacher* and *Porter* decisions
- § 2:7 —The *Hancock* and *Tapert* decisions and beyond
- § 2:8 The Medicare and Medicaid Anti-fraud and Abuse Amendments of 1977
- § 2:9 The Omnibus Reconciliation Act of 1980—The requirement of specific intent
- § 2:10 The Medicare-Medicaid Patient and Program Protection Act of 1987
- § 2:11 Health reform
- § 2:12 The Eliminating Kickbacks in Recovery Act of 2018
- § 2:13 The statutory exceptions
- § 2:14 —Discounts
- § 2:15 —Employer/employee
- § 2:16 —Group purchasing organizations (GPOs)
- § 2:17 —Waivers of coinsurance obligations
- § 2:18 —Managed care organizations (MCOs)
- § 2:19 Additional statutory exceptions
- § 2:20 Health Reform regarding Charitable and Other Innocuous Programs
- § 2:21 The statutory exceptions—Other practices
- § 2:22 *Bay State Ambulance*

## TABLE OF CONTENTS

§ 2:23	Agency interpretations of the amended anti-kickback provisions
§ 2:24	—HCFA’s advisory letters and opinions
§ 2:25	—The intermediary letters
§ 2:26	—Informal guidance letters
§ 2:27	—The OIG special fraud alerts
§ 2:28	The original safe harbor regulations and clarifications of the statutory exceptions
§ 2:29	The original safe harbor regulations—The investment interests safe harbor—42 C.F.R. § 1001.952(a)
§ 2:30	— —Large publicly traded corporations
§ 2:31	— —Investments in small entities
§ 2:32	— —November 1999 amendment to safe harbor for investment interests in underserved areas
§ 2:33	—Space rental safe harbor—42 C.F.R. § 1001.952(b)
§ 2:34	—Equipment rentals safe harbor—42 C.F.R. § 1001.952(c)
§ 2:35	—Safe harbor for personal services and management contracts—42 C.F.R. § 1001.952(d)
§ 2:36	The original safe harbor regulations and clarifications of the statutory exceptions—Safe harbor for the sale of a physician practice—42 C.F.R. § 1001.952(e)
§ 2:37	—The safe harbor for referral services—42 C.F.R. § 1001.952(f)
§ 2:38	—The safe harbor for warranties—42 C.F.R. § 1001.952(g)
§ 2:39	—The discount safe harbor—42 C.F.R. § 1001.952(h)
§ 2:40	—The employer/employee safe harbor—42 C.F.R. § 1001.952(i)
§ 2:41	—The GPO safe harbor—42 C.F.R. § 1001.952(j)
§ 2:42	—Waiver of copayment, coinsurance and deductible amounts—42 C.F.R. § 1001.952(k)
§ 2:43	—The safe harbor for increased coverage, reduced cost-sharing and reduced premiums offered by health plans—42 C.F.R. § 1001.952(l)
§ 2:44	—The safe harbor for price reductions offered to Managed Care Organizations (MCOs)—42 C.F.R. § 1001.952(m)
§ 2:45	— —Price reductions offered to risk-based managed care health plans
§ 2:46	— —Price reductions offered to cost-based managed care health plans
§ 2:47	— —Price reductions offered by contract health care providers not at-risk to health plans
§ 2:48	— —Price reductions offered to health plans by contract health care providers paid on at-risk basis
§ 2:49	The 1999 safe harbors
§ 2:50	—The safe harbor for practitioner recruitment—42 C.F.R. § 1001.952(n)

MEDICARE AND MEDICAID FRAUD AND ABUSE

- § 2:51 —The safe harbor for obstetrical malpractice insurance subsidies—42 C.F.R. § 1001.952(o)
- § 2:52 —The safe harbor for investment interests in group practices—42 C.F.R. § 1001.952(p)
- § 2:53 —The safe harbor for cooperative hospital service organizations—42 C.F.R. § 1001.952(q)
- § 2:54 —The safe harbor for investment interests in ambulatory surgical centers—42 C.F.R. § 1001.952(r)
- § 2:55 —The safe harbor for referral agreements for specialty services—42 C.F.R. § 1001.952(s)
- § 2:56 —The safe harbor for price reductions offered to Eligible Managed Care Organizations (EMCOs)—42 C.F.R. § 1001.952(t)
- § 2:57 —Safe harbor for price reductions offered by contractors with substantial financial risk to managed care organizations—42 C.F.R. § 1001.952(u)
- § 2:58 Safe harbor for ambulance restocking practices—42 C.F.R. § 1001.952(v)
- § 2:59 Health Centers—42 C.F.R. § 1001.952(w)
- § 2:60 E-health prescribing and electronic health records—42 C.F.R. § 1001.952(x) and (y)
- § 2:61 Final waivers in connection with the Shared Savings Program
- § 2:62 The 2016 safe harbors
- § 2:63 —FQHCs and Medicare Advantage Organizations—42 C.F.R. § 1001.952(z)
- § 2:64 —Medicare Coverage Gap Discount Program—42 C.F.R. § 1001.952(aa)
- § 2:65 —Local Transportation—42 C.F.R. § 1001.952(bb)
- § 2:66 The 2020 safe harbors
- § 2:67 —The Value-Based Safe Harbors and Their Common Definitions
- § 2:68 —Care coordination arrangements to improve quality, health outcomes, and efficiency—42 CFR § 1001.952(ee)
- § 2:69 —Value-based arrangements with substantial downside financial risk—42 CFR § 1001.952(ff)
- § 2:70 —Value-based arrangements with full financial risk—42 CFR § 1001.952(gg)
- § 2:71 —Arrangements for patient engagement and support to improve quality, health outcomes, and efficiency—42 CFR § 1001.952(hh)
- § 2:72 —CMS-sponsored model arrangements and CMS-sponsored model patient incentives—42 CFR § 1001.952(ii)
- § 2:73 —Cybersecurity technology and related services—42 CFR § 1001.952(jj)

TABLE OF CONTENTS

- § 2:74 —ACO Beneficiary Incentive Program—42 CFR § 1001.952(kk)
- § 2:75 The intent requirements of the anti-kickback statute
- § 2:76 —Purpose to induce future referrals
- § 2:77 —Knowledge of the law
- § 2:78 —The aftermath of *Hanlester* and acquittal of *Caremark* defendants
- § 2:79 —The courts split: The *Jain, Neufeld* and *Davis* decisions
- § 2:80 —State court reaction to *Hanlester*—*Medical Development Network*
- § 2:81 —The impact of *Bryan v. U.S.* on the proper construction of “willfully”
- § 2:82 — —The *Bryan* decision
- § 2:83 — —Implications for anti-kickback willfulness
- § 2:84 — —Are the anti-kickback rules “highly technical”?—*U.S. v. Starks*
- § 2:85 Health Reform
- § 2:86 The “advice of counsel defense”
- § 2:87 —The prosecution of attorneys for advice given to health care offenders—*U.S. v. Anderson*
- § 2:88 The Definition of “Referral”
- § 2:89 The special fraud alerts
- § 2:90 —Joint venture arrangements
- § 2:91 — —Special fraud alert—The manner of selection and retention of investors
- § 2:92 — — —Financing and profit distribution agreements
- § 2:93 — — —The business structure of the joint venture
- § 2:94 — —Exclusion efforts against joint ventures: The *Hanlester Network* case
- § 2:95 —Special fraud alert on routine waiver of Medicare Part B copayments and deductibles
- § 2:96 —Special fraud alert on physician recruitment and other hospital incentive practices
- § 2:97 —Special fraud alert on prescription drug marketing practices
- § 2:98 —Special fraud alert on arrangements for the provision of clinical laboratory services
- § 2:99 —Special fraud alert on home health care fraud
- § 2:100 —Special fraud alert on the provision of medical supplies to nursing home facilities
- § 2:101 —Special fraud alert on the provision of services in nursing facilities
- § 2:102 —Special fraud alert on fraud and abuse in nursing home arrangements with hospices
- § 2:103 —Special fraud alert on physician certifications for medical equipment, supplies and home health services

MEDICARE AND MEDICAID FRAUD AND ABUSE

- § 2:104 —Telemarketing by Durable Medical Equipment Suppliers
- § 2:105 Special Advisory Bulletin—Effect of exclusion
- § 2:106 Special Advisory Bulletin on the Patient Anti-Dumping Statute
- § 2:107 The special fraud alerts—Special fraud alert on rental of space in physician offices
- § 2:108 Special Advisory Bulletin on Practices of Business Consultants
- § 2:109 The special fraud alerts—Request for fraud alert on “economic credentialing” arrangements
- § 2:110 Special Advisory Bulletin on Offering Gifts and Other Inducements to Beneficiaries
- § 2:111 The special fraud alerts—OIG letter regarding transportation programs
- § 2:112 —OIG special fraud alert on telemarketing by DME suppliers
- § 2:113 —OIG alert against misuse of HHS words, symbols, emblems
- § 2:114 —Malpractice assistance guidance
- § 2:115 —Special advisory bulletin on contractual joint ventures
- § 2:116 —Physician-owned Entities
- § 2:117 The special fraud alerts: Laboratory payments to referring physicians
- § 2:118 The special fraud alerts—Speaker Programs
- § 2:119 —Arrangements with telemedicine companies
- § 2:120 —Suspect payments in marketing arrangements related to medicare advantage providers
- § 2:121 OIG Alert—Concierge care
- § 2:122 Hospital discounts to the uninsured
- § 2:123 Education and outreach agreements under the Medicare Discount Drug Program
- § 2:124 Physician and device manufacturer joint ventures
- § 2:125 Special Advisory Bulletin on Patient Assistance Programs for Medicare Part D Enrollees
- § 2:126 Fraud Alert—Physician Compensation Arrangements
- § 2:127 OIG Policy Reminder—Information Blocking
- § 2:128 OIG Policy Statement—Hospital not charging for self-administered drugs
- § 2:129 The requirement of advisory opinions
- § 2:130 Availability of advisory opinions—Summary of procedures
- § 2:131 Frequently asked questions
- § 2:132 Volume of opinions
- § 2:133 Advisory Opinion about physicians
- § 2:134 Advisory Opinion about hospitals
- § 2:135 Advisory Opinion about other sectors

## TABLE OF CONTENTS

- § 2:136 Some practicalities
- § 2:137 Voluntary Disclosure Protocol
- § 2:138 Legal complications?
- § 2:139 Conclusion
- § 2:140 Key questions

## **CHAPTER 3. THE STARK STATUTE AND REGULATIONS**

- § 3:1 Introduction—The self-referral problem
- § 3:2 Stark versus anti-kickback
- § 3:3 Anti-markup rules
- § 3:4 The Stark prohibitions
- § 3:5 Designated health services
- § 3:6 An entity
- § 3:7 By a physician
- § 3:8 A referral
- § 3:9 Financial relationships
- § 3:10 Compensation arrangements
- § 3:11 “Stand in the shoes”
- § 3:12 Stark statutory exceptions—Generally
- § 3:13 Statutory ownership and compensation arrangement exceptions
- § 3:14 —The physicians’ services exception
- § 3:15 —The in-office ancillary services exception
- § 3:16 Who renders the service
- § 3:17 Where the services are rendered
- § 3:18 Who bills for the service
- § 3:19 Alternative advanced diagnostic imaging notice
- § 3:20 Statutory ownership and compensation arrangement exceptions—The definition of a group
- § 3:21 Structure
- § 3:22 Unified business
- § 3:23 Profit-Sharing
- § 3:24 Productivity Bonuses
- § 3:25 Statutory ownership and compensation arrangement exceptions—Rural provider exception
- § 3:26 Statutory Ownership and compensation arrangement exceptions—Prepaid health plans
- § 3:27 Statutory ownership and investment interest exceptions
- § 3:28 —Publicly traded securities
- § 3:29 —Physician-Owned Hospitals
- § 3:30 The referral problem
- § 3:31 The moratorium—Now over
- § 3:32 Health Reform restrictions
- § 3:33 Increasing beds and ORs

MEDICARE AND MEDICAID FRAUD AND ABUSE

- § 3:34 Disclosure of ownership
- § 3:35 Statutory compensation exceptions—Definitions
- § 3:36 Fair market value
- § 3:37 Volume or value
- § 3:38 Commercial reasonableness
- § 3:39 Statutory compensation exceptions—Rental of space and equipment
  - § 3:40 —Bona-fide employment arrangements
  - § 3:41 —Personal services contracts
  - § 3:42 —Physician incentive plans
  - § 3:43 —Compensation by hospitals
  - § 3:44 Physician recruitment
  - § 3:45 Physician Retention
  - § 3:46 Statutory compensation exceptions—Isolated transactions
    - § 3:47 —Group practice arrangements with hospitals
    - § 3:48 —Physician purchases of services
    - § 3:49 Statutory compensation exception—Wellness programs
  - § 3:50 Regulatory compensation exceptions
  - § 3:51 Definitions—“Stand in the Shoes”
    - § 3:52 —Locum Tenens
  - § 3:53 Academic Medical Centers
  - § 3:54 Fair Market Value Compensation
  - § 3:55 Medical Staff Incidental Benefits
  - § 3:56 Non-Monetary Compensation
  - § 3:57 Risk Sharing Arrangements
  - § 3:58 Compliance Training
  - § 3:59 Indirect Compensation Arrangements
  - § 3:60 “Under Arrangements”
  - § 3:61 NPP Recruitment Assistance
  - § 3:62 Timeshare Arrangements
  - § 3:63 Obstetrical malpractice payments and referral services
  - § 3:64 Professional courtesy
  - § 3:65 Charitable donations by physicians
  - § 3:66 Community wide information systems
  - § 3:67 Permitted directed referrals
  - § 3:68 Limited remuneration to a physician
  - § 3:69 Electronic health records, e-prescribing and cybersecurity
    - § 3:70 —e-Prescribing
    - § 3:71 —Electronic Health Records
    - § 3:72 —Cybersecurity software and services
  - § 3:73 Value-based Arrangements
    - § 3:74 —Definitions
    - § 3:75 —Full Financial Risk
    - § 3:76 —Meaningful downside financial risk to the physician
    - § 3:77 —Value-Based Arrangements

## TABLE OF CONTENTS

- § 3:78 Rural emergency hospitals
- § 3:79 Burden reduction—“Written Agreement”
- § 3:80 —Holdovers
- § 3:81 Temporary Non-Compliance
- § 3:82 Compliance
- § 3:83 Issues susceptible of correction
- § 3:84 Determining the period of disallowance
- § 3:85 Limited grace period
- § 3:86 COVID Waivers
- § 3:87 The Self-Referral Disclosure Protocol (SRDP)
- § 3:88 Reporting requirements
- § 3:89 Advisory Opinions
- § 3:90 Settlements
- § 3:91 Caselaw
- § 3:92 Stark application to Medicaid
- § 3:93 State self-referral laws
- § 3:94 Key questions in analyzing the effect of Stark on a physician-relevant transaction

## **CHAPTER 4. ADMINISTRATIVE PENALTIES AND EXCLUSIONS**

- § 4:1 Introduction
- § 4:2 Exclusions, denials, and terminations—Generally
- § 4:3 —Mandatory exclusions
- § 4:4 —Permissive exclusions
- § 4:5 Guidance for implementing permissive exclusion
- § 4:6 Exclusions, denials, and terminations—Consequences of exclusion
- § 4:7 —Program termination versus exclusion
- § 4:8 Procedures for imposing exclusions
- § 4:9 Civil money penalty authorities
- § 4:10 The Sunshine Act
- § 4:11 Quality relevant CMPs
- § 4:12 Administrative penalties for false claims
- § 4:13 Who and how much is assessed?
- § 4:14 Procedures for imposing civil money penalties and assessments
- § 4:15 Other sanctions and administrative remedies including payment suspension
- § 4:16 State exclusion and civil money penalty statutes
- § 4:17 Key questions

## **CHAPTER 5. FALSE CLAIMS: CRIMINAL, CIVIL, AND QUI TAM ACTIONS**

- § 5:1 Introduction
- § 5:2 Criminal false claims prosecutions

## MEDICARE AND MEDICAID FRAUD AND ABUSE

- § 5:3 —Federal health care offenses under the Health Insurance Portability and Accountability Act of 1996 and Beyond
- § 5:4 —18 U.S.C.A. § 287, false claims
- § 5:5 —18 U.S.C.A. § 1001, false statements
- § 5:6 —18 U.S.C.A. § 1341, mail fraud
- § 5:7 —Miscellaneous crimes
- § 5:8 —Federal health care program fraud
- § 5:9 Federal civil false claims
- § 5:10 Civil false claims prosecuted
- § 5:11 To whom
- § 5:12 “Knowingly”
- § 5:13 —Falsity
- § 5:14 Implied Certification and Materiality
- § 5:15 Particularity
- § 5:16 Corporate Liability
- § 5:17 Fraud Enforcement and Recovery Act and Health Reform
- § 5:18 Voluntary Repayments and Self-Disclosures
- § 5:19 *Qui tam* actions
- § 5:20 False claims education requirement
- § 5:21 Beneficiary incentive program
- § 5:22 Standing to bring *qui tam* actions
- § 5:23 —The public disclosure limitation exception—Pre Health Reform
- § 5:24 — —Post-Health Reform
- § 5:25 The original source exception to the public disclosure bar
- § 5:26 Standing to bring *qui tam* actions—Potential plaintiffs
- § 5:27 Procedural and remedial issues in *qui tam* actions— Filing requirements
- § 5:28 —Dismissal and settlement
- § 5:29 —The relator’s share
- § 5:30 Whistleblower protection provisions against retaliation
- § 5:31 Constitutionality of the *qui tam* statute
- § 5:32 Procedural issues in civil false claims litigation— Statute of limitations, venue and jurisdiction
- § 5:33 —Immunity of state defendants from FCA litigation
- § 5:34 —Discovery
- § 5:35 Damages and penalties in civil false claims litigation
- § 5:36 Constitutional Limitations on False Claims Act penalties
- § 5:37 State false claims law
- § 5:38 Key questions

## CHAPTER 6. INVESTIGATIONS

- § 6:1 Introduction

## TABLE OF CONTENTS

- § 6:2 The key players
- § 6:3 The United States Department of Justice (DOJ)
- § 6:4 —Policies on Corporate Enforcement and Individual Responsibility
- § 6:5 —The U.S. Attorneys’ Offices (USAOs)
- § 6:6 —The Federal Bureau of Investigation (FBI)
- § 6:7 —Other federal investigative agencies
- § 6:8 The Office of Inspector General Department of Health and Human Service (HHS)
- § 6:9 —Centers for Medicare and Medicaid Services (CMS)
- § 6:10 —Medicare Administrative Contractors and intermediaries
- § 6:11 —Peer review organizations (PROs)
- § 6:12 Medicaid fraud control units (MFCUs)
- § 6:13 Whistleblowers
- § 6:14 Dismissal of meritless whistleblower actions
- § 6:15 Government Databases
- § 6:16 Common investigative methods
- § 6:17 The subpoena power
- § 6:18 Grand jury investigations
- § 6:19 —The grand jury power to investigate
- § 6:20 Administrative investigation
- § 6:21 Administrative subpoenas for personal records
- § 6:22 DOJ or HIPAA subpoenas
- § 6:23 Civil investigative demands (CIDs)
- § 6:24 Undercover investigations
- § 6:25 Search warrants
- § 6:26 Administrative searches
- § 6:27 The Fifth Amendment privilege against self-incrimination
- § 6:28 —Act of production as testimonial communication
- § 6:29 —The required records exception
- § 6:30 —Grants of immunity
- § 6:31 Challenges to subpoenas under the Fourth Amendment prohibition against unreasonable searches and seizures
- § 6:32 Challenging administrative subpoenas
- § 6:33 —Challenges based on breadth and burdensomeness
- § 6:34 —The problem of subterfuge
- § 6:35 Challenges to search warrants under the Fourth Amendment—Lack of probable cause
- § 6:36 —Insufficient particularity
- § 6:37 —Unauthorized party involved in search
- § 6:38 —Public versus private searches
- § 6:39 Motions for return of seized documents
- § 6:40 Privilege claims
- § 6:41 —The physician-patient privilege

## MEDICARE AND MEDICAID FRAUD AND ABUSE

- § 6:42 —The psychologist-patient privilege
- § 6:43 — —The federal privilege
- § 6:44 —The psychotherapist-patient privilege—State privileges
- § 6:45 —The attorney-client privilege
- § 6:46 —The “advice of counsel” limitation
- § 6:47 —The work product protection
- § 6:48 —The joint defense attorney-client privilege
- § 6:49 Attorney’s guide to common responses to an investigation
- § 6:50 Conducting internal investigations
- § 6:51 Potential civil, criminal and administrative exposures
- § 6:52 Recent Amendments to the Federal Sentencing Guidelines
- § 6:53 Case studies
- § 6:54 The oblivious medical practice—How to determine if you are under investigation
- § 6:55 The tale of a fake drug—How to respond to an active government investigation
- § 6:56 Key questions

## **APPENDICES**

Appendix A. Internet Resources for Health Law

Appendix B. Stark v. Anti-kickback Comparator

**Table of Laws and Rules**

**Table of Cases**

**Index**